Martin Bauer Group has acquired plant-based ingredients manufacturer BI Nutraceuticals as it targets accelerated growth in the US.
Based in California, BI Nutraceuticals supplies a range of botanical, nutritional and value-added ingredients for the food and beverage, dietary supplement and personal care industries.
Botanical ingredients provider Martin Bauer said the acquisition will create “an extensive portfolio of botanical ingredients and a versatile manufacturing hub”. As part of the deal, the two companies will continue to operate independently.
Ennio Ranaboldo, CEO of Martin Bauer Group in North America, said: “The addition of BI Nutraceuticals to our group buttresses our commitment to reliable, quality, safe and clean-label raw materials, meeting an increasing demand from our customers and consumers.”
BI Nutraceuticals CEO George Pontiakos said: “This represents a significant move forward for us and our combined customer base. The Martin Bauer Group is a family-owned international company with a long history as a manufacturer and supplier of teas, extracts and botanical products going back more than 135 years.
“BI Nutraceuticals will now have access to the global resources of the Martin Bauer Group in the areas of raw materials sourcing, processing technology, liquid extract production and research and development.
“As part of the Martin Bauer Group, we become a true single-source solution provider. Our customers can be even more confident in our long-standing commitment to safety, quality, service and innovation.”
With products sourced from more than 80 countries, Martin Bauer has more than 20 manufacturing sites and sales units worldwide. The company has around 3,600 employees.
Last December, the firm doubled the size of its tea extract manufacturing facility in Hangzhou, China. The new 200,000-square-foot unit expands the site’s capacity for green and black tea extracts to meet rising global demand.
By Jules Scully
Cécile Béliot has assumed the role of Bel Group chief executive officer, following the decision to separate the roles of chairman and CEO. The separation of the functions will enable Bel Group to develop in three areas of healthy snacking. Meanwhile, the company’s former CEO, Antoine Fiévet, has had his mandate renewed as chairman of the board.
US Food and Drug Administration (FDA) Commissioner Dr. Robert Califf was grilled by lawmakers during a House Appropriations subcommittee hearing, where he was slammed over the agency’s handling of the escalating infant formula shortage.
Sweegen is ramping up its efforts to reduce sugar across F&B applications while simultaneously tapping into the benefits of using antioxidants and bitter blocking technology. Speaking to FoodIngredientsFirst, Casey McCormick, vice president of global innovation at Sweegen, says product developers can find a broad range of solutions in Sweegen’s nature-based sweetener systems as brands elevate better-for-you foods.